After 72 weeks, participants who received the higher dose achieved an average body-weight reduction of 18.8%, compared with 3.9% among participants who received placebo
These conditions result in the overproduction of AGEs, accumulation of pro-inflammatory and pro-fibrotic factors, and free fatty acid oxidation
Difficulty swallowing (dysphagia) or pain when swallowing, which may indicate oesophageal complications and requires urgent assessment at any age
Ahmed AM, Lopez I, Perese F, Vasquez R, Hynan LS, Chong B, et al A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma JAMA Dermatol
CIMA, Agencia Espaola de Medicamentos y Productos Sanitarios
Additionally, Novo Nordisk will present mid-stage Phase 2 results for zenagamtide, an investigational peptide therapy targeting metabolic disorders